Idarubicin Hydrochloride

DRUG13 trials

Sponsors

GPOH gGmbH, Fondazione Gimema Franco Mandelli Onlus, Assistance Publique Hopitaux De Paris, Oxcia AB, Oxcia AB, Thomas Helledays Stiftelse Foer Medicinsk Forskning, Syndax Pharmaceuticals Inc.

Conditions

AML, ChildhoodAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapyAdult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.C-KIT MutationChronic Myelomonocytic Leukemia-2Core Binding Factor Acute Myeloid Leukemia

Early Phase 1

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

RecruitingNCT07059975

Joanna YiAcute Myeloid Leukemia, Pediatric AML

Start: 2025-10-22End: 2031-08-31Target: 36Updated: 2025-11-04

Phase 1

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

CompletedNCT02029950

National Cancer Institute (NCI)Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia-2, High Risk Myelodysplastic Syndrome +1

Start: 2013-12-16End: 2020-05-13Updated: 2020-10-14

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Active, not recruitingNCT04190550

National Cancer Institute (NCI)Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Start: 2021-02-04End: 2026-06-30Target: 24Updated: 2026-04-03

MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib

RecruitingCTIS2024-513766-20-00

Oxcia AB, Oxcia AB, Thomas Helledays Stiftelse Foer Medicinsk ForskningHematological malignancies

Start: 2019-12-03Target: 31Updated: 2026-01-22

SALMA Study - Phase I/II Clinical Trial Assessing the Combination of Sulfasalazine with Standard of Care Induction Therapy in Newly Diagnosed Non-Favorable Acute Myeloid Leukemias (AML) Patients 60 years or older

RecruitingCTIS2024-513084-38-00

Assistance Publique Hopitaux De ParisRecently diagnosed non favorable Acute Myeloid Leukemias

Start: 2025-04-15Target: 64Updated: 2025-05-16

Phase 2

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Active, not recruitingNCT04214249

National Cancer Institute (NCI)Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy +1

Start: 2021-02-17End: 2027-01-30Updated: 2026-04-03

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

SuspendedNCT05955261

St. Jude Children's Research HospitalAcute Myeloid Leukemia

Start: 2023-07-25End: 2034-03-31Target: 70Updated: 2025-12-09

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

RecruitingNCT06221683

Children's Hospital of Soochow UniversityAcute Myeloid Leukemia, AML, Childhood

Start: 2024-01-01End: 2029-12-31Target: 500Updated: 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

RecruitingNCT06316960

Children's Hospital of Soochow UniversityAML, Childhood, C-KIT Mutation, Core Binding Factor Acute Myeloid Leukemia +2

Start: 2024-03-01End: 2027-03-31Target: 50Updated: 2024-08-22

Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) - BALLik. ALL2922

RecruitingCTIS2023-510240-20-00

Fondazione Gimema Franco Mandelli OnlusAdult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

Start: 2022-10-05Target: 32Updated: 2025-05-13

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024

RecruitingCTIS2024-511627-34-00

Fondazione Gimema Franco Mandelli OnlusVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

Start: 2024-10-17Target: 31Updated: 2025-12-23

Phase 3

International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents

RecruitingCTIS2022-500783-35-00

GPOH gGmbHAcute Myeloid Leukemia

Start: 2022-12-06Target: 1091Updated: 2025-09-25

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

Not yet recruitingCTIS2025-522279-27-00

Syndax Pharmaceuticals Inc.Newly Diagnosed AML with an NPM1 mutation

Target: 21Updated: 2026-02-13

Related Papers

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975)

Blood2025-11-03

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Blood2024-11-05

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Journal for ImmunoTherapy of Cancer2022-01-0172 citations

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Blood2020-11-046 citations